Posts tagged BTIG
BTIG ups KalVista price target to $27

BTIG raised its price target for KalVista Pharmaceuticals (NASDAQ:KALV) to $27 from $18 after the company inked a multifaceted collaboration with Merck (NYSE:MRK) last week. The stock closed at $9.74 on Oct. 13.

Read More
BTIG starts Clementia at buy

BTIG initiated coverage of Clementia Pharmaceuticals (NASDAQ:CMTA) with a “buy” rating and 12-month price target of $32, saying the company’s lead molecule, palovarotene, presents a plethora of promising possibilities. The stock closed at $16.01 on August 30.

Read More
BTIG starts Eiger BioPharma at buy

BTIG initiated coverage of Eiger BioPharmaceuticals (NASDAQ:EIGR) with a “buy” rating and $32 price target. The stock closed at $7.45 on July 13.

Read More
Karen Koski joins Oxford Immunotec as head of strategy

Oxford Immunotec Global (NASDAQ:OXFD) has appointed Karen Koski as head of strategy and investor relations, a newly created position that will report directly to CEO, Peter Wrighton-Smith. The appointment is effective on June 21.

Read More
BTIG starts Axsome at buy

BTIG launched coverage of Axsome Therapeutics (NASDAQ:AXSM) with a “buy” rating and $14 price target. The stock closed at $3.80 on May 18.

Read More
BTIG starts Quotient at buy

BTIG initiated coverage of Quotient (NASDAQ:QTNT) with a “buy” rating and $22 price target. The stock closed at $6.26 on April 17.

Read More
BTIG starts Intra-Cellular Therapies at buy

BTIG launched coverage of Cellular Therapies (NASDAQ:ITCI) with a “buy” rating and $44 price target, saying there is considerable promise for the company’s antipsychotic, ITI-007, in multiple indications. The stock closed at $15.05 on Dec. 21.

Read More